phase readout
saveNCT05055258: A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II
TERMINATEDupdated 8m ago
community read0 votes
Sponsor: KalVista Pharmaceuticals, Ltd.. Phase: PHASE2. Conditions: Angioedema, Hereditary, Types I and II
view source ↗
comments(0)
5-min edit window · permanent after that